FERTIN PHARMA
LIVE

Serial Number

98326058

Owner

Fertin Pharma A/S

Attorney

Tamar Niv Bessinger

Filing Date

Dec 21, 2023

Add to watchlist:

No watchlists yet
View on USPTO

FERTIN PHARMA Trademark

Serial Number: 98326058

FERTIN PHARMA is a trademark filed by Fertin Pharma A/S on December 21, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Fertin Pharma A/S (19 trademarks)

Industrivej 8

Entity Type: 16

Trademark Details

Filing Date

December 21, 2023

Registration Date

Not Registered

Published for Opposition

October 15, 2024

Goods & Services

Pharmaceutical preparations, namely, smoking cessation preparations, analgesic preparations, sleep aid- preparations, anti-pyretic and anti-inflammatory preparations, preparations for the treatment of arthritis, preparations having psychotherapeutic properties, preparations for treatment of cold, flu, cough, sinus, allergy, cardiovascular emergencies, neurological conditions, chronic pain management, and gastro-intestinal disorders; pharmaceutical preparations, namely, smoking cessation preparations, analgesic preparations, sleep aid-preparations, anti-pyretic and anti-inflammatory preparations, preparations for the treatment of arthritis, preparations having psychotherapeutic properties, preparations for treatment of cold, flu, cough, sinus, allergy, cardiovascular emergencies, neurological conditions, chronic pain management, and gastro-intestinal disorders in chewable form, in gum form, in lozenge form, and in pouch powder form; aerosolized and inhaled therapeutics and pharmaceuticals, namely, smoking cessation preparations, analgesic preparations, sleep aid-preparations, anti- pyretic and anti-inflammatory preparations, preparations for the treatment of arthritis, preparations having psychotherapeutic properties, preparations for treatment of cold, flu, cough, sinus, allergy, cardiovascular emergencies, neurological conditions, chronic pain management, and gastro-intestinal disorders; pharmaceutical preparations for inhalation, namely, smoking cessation preparations, analgesic preparations, sleep aid-preparations, anti-pyretic and anti-inflammatory preparations, preparations for the treatment of arthritis, preparations having psychotherapeutic properties, preparations for treatment of cold, flu, cough, sinus, allergy, cardiovascular emergencies, neurological conditions, chronic pain management, and gastro-intestinal disorders; drug delivery agents in the form of fast liquefiable tablets, compressed gum, extruded gum, lozenges, pouch powder, dissolvable films, coatings for tablets, and transdermal patches that facilitate the delivery of pharmaceutical preparations, namely, smoking cessation preparations, analgesic preparations, sleep aid-preparations, anti-pyretic and anti-inflammatory preparations, preparations for the treatment of arthritis, preparations having psychotherapeutic properties, preparations for treatment of cold, flu, cough, sinus, allergy, cardiovascular emergencies, neurological conditions, chronic pain management, and gastro-intestinal disorders; vitamins and dietary supplements; dietetic foodstuffs adapted for medical purposes; nicotine gum for use as an aid to stop smoking; medicated chewing gum as a drug delivery agent to facilitate the delivery of pharmaceutical preparations; dietetic preparations for medical use; herbal extracts for medical purposes; herbal teas for medicinal purposes

Scientific, medical and technological services and research and design relating thereto namely, research and development of technology in the field of smoking cessation preparations, analgesic preparations, sleep aid-preparations, anti-pyretic and anti-inflammatory preparations, preparations for the treatment of arthritis, preparations having psychotherapeutic properties, preparations for treatment of cold, flu, cough, sinus, allergy, cardiovascular emergencies, neurological conditions, chronic pain management, and gastro-intestinal disorders; industrial analysis and industrial research services in the field of pharmaceutical research and development services; research, and development of pharmaceutical preparations for treatment of a wide variety of conditions in chewable form, in gum form, in lozenge form, and in pouch powder form; research and development of inhaled therapeutics; research, and development of pharmaceuticals and well-being products for oral and intra-oral delivery systems; research and development of pharmaceuticals for smoking cessation; provision of advice, information and consultancy in relation to the aforesaid service

Custom manufacture of pharmaceuticals and nutraceuticals; consultancy regarding the custom manufacture of pharmaceuticals and nutraceuticals; custom manufacture of pharmaceuticals, namely, formulation of pharmaceutical preparations for treatment of a wide variety of conditions in chewable form, in gum form, in lozenge form, and in pouch powder form; custom manufacture of pharmaceuticals, namely, formulation of inhaled therapeutics; custom manufacture of pharmaceuticals, namely, formulation of pharmaceuticals and well-being products for oral and intra-oral delivery systems; research, and development of pharmaceuticals and well-being products for oral and intra-oral delivery systems; custom manufacture of pharmaceuticals, namely, formulation of pharmaceuticals for smoking cessation; provision of advice, information and consultancy in relation to the aforesaid services

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 17, 2026 EXRA
SOU EXTENSION 3 GRANTED
May 15, 2026 EX3G
SOU EXTENSION 3 FILED
May 15, 2026 EXT3
SOU TEAS EXTENSION RECEIVED
May 15, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 26, 2025 EXRA
SOU EXTENSION 2 GRANTED
Nov 25, 2025 EX2G
SOU EXTENSION 2 FILED
Nov 25, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Nov 25, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 4, 2025 EXRA
SOU EXTENSION 1 GRANTED
Jan 14, 2025 EX1G
SOU EXTENSION 1 FILED
Jan 13, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Jan 13, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 26, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 15, 2024 NPUB
PUBLISHED FOR OPPOSITION
Oct 15, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 25, 2024 NONP
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Sep 5, 2024 ERRR
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 4, 2024 CNSA
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Sep 4, 2024 AMPX
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 21, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 21, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 21, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 24, 2024 GNRN
NON-FINAL ACTION E-MAILED
May 24, 2024 GNRT
NON-FINAL ACTION WRITTEN
May 24, 2024 CNRT
ASSIGNED TO EXAMINER
May 23, 2024 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Apr 3, 2024 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 2, 2024 NWOS
TEAS VOLUNTARY AMENDMENT RECEIVED
Jan 2, 2024 PARI
NEW APPLICATION ENTERED
Dec 21, 2023 NWAP